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Abstract
By analyzing the exome sequences of 2,536 schizophrenia cases and 2,543 controls, we have
demonstrated a polygenic burden primarily arising from rare (<1/10,000), disruptive mutations
distributed across many genes. Especially enriched genesets included the voltage-gated calcium
ion channel and the signaling complex formed by the activity-regulated cytoskeleton-associated
(ARC) scaffold protein of the postsynaptic density (PSD), sets previously implicated by genome-
wide association studies (GWAS) and copy-number variation (CNV) studies. Similar to reports in
autism, targets of the fragile × mental retardation protein (FMRP, product of FMR1) were
enriched for case mutations. No individual gene-based test achieved significance after correction
for multiple testing and we did not detect any alleles of moderately low frequency (~0.5-1%) and
moderately large effect. Taken together, these data suggest that population-based exome
sequencing can discover risk alleles and complements established gene mapping paradigms in
neuropsychiatric disease.
Genetic studies of schizophrenia (MIM: 181500) have demonstrated a substantial
heritability (Sullivan et al., 2003; Lichtenstein et al., 2009) that reflects common and rare
alleles at many loci. Genome-wide association studies (GWAS) continue to uncover
common single nucleotide polymorphisms (SNPs) at novel loci (Ripke et al., 2013). Rare or
de novo genic deletions and duplications (copy number variants, CNV) have been firmly
established, including risk variants at 22q11.2, 15q13.3, 1q21.1 (Levinson et al, 2011;
Sullivan et al., 2012). One striking outcome of these large-scale, genome-wide
investigations is the degree of polygenicity, consistent with thousands of genes and non-
coding loci harboring risk alleles (International Schizophrenia Consortium, 2008, 2009; Lee
et al., 2012; Ripke et al, 2013; Malhotra & Sebat, 2012).
Nonetheless, progress has been made in implicating biological systems and quantifying
shared genetics among related psychiatric disorders (e.g. Psychiatric Genomics Bipolar
Disorder Working Group, 2011; Moreno-De-Luca et al., 2010); for example, in pointing to
common variants in calcium ion channel genes impacting schizophrenia and bipolar disorder
(Cross-Disorder Group of the Psychiatric Genomics Consortium, 2013) and to de novo
CNVs impacting genes encoding members of the postsynaptic density (PSD) proteome
(Kirov et al., 2012), in particular members of the neuronal ARC protein and N-methyl-D-
aspartate receptor (NMDAR) postsynaptic signaling complexes.
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Here we apply massively parallel short-read sequencing to assay a substantial portion of
variation that previously was effectively invisible: rare coding point mutations (single
nucleotide variants, SNVs) and small insertions and deletions (indels). Although previous
schizophrenia studies have applied sequencing, the results have been inconclusive, reflecting
limited sample sizes or a focus on small numbers of candidate genes (Need et al., 2012;
Crowley et al., 2013; Takata et al., 2013; Timms et al., 2013). Exome-sequencing studies of
de novo mutation published to date have neither demonstrated an increased rate in
schizophrenia, nor conclusively implicated individual genes (Girard et al., 2011, Xu et al.,
2012), although some data suggest a link with particular classes of gene, such as those with
higher brain expression in early fetal life (Xu et al., 2012). De novo studies in intellectual
disability (ID, de Ligt et al., 2012; Rauch et al., 2012) and autism (Iossifov et al., 2012;
Neale et al., 2012; O’ Roak et al., 2012; Sanders et al., 2012) have made significant progress
in identifying large-effect alleles and the underlying gene networks, however.
In this study, we sought to identify the alleles, genes or gene networks that harbor rare
coding variants of moderate or large effect on risk for schizophrenia by exome-sequencing
5,079 individuals, selected from a Swedish sample of more than 11,000 individuals.
Previous analyses of the full sample (SI section 1) have demonstrated an enriched burden of
rare CNVs and a polygenic common variant component (Ripke et al., 2013). We generated
high coverage exome sequence to ensure sufficient sensitivity to detect and genotype alleles
observed in only one heterozygous individual (singletons, implying an allele frequency of
~1/10,000 although the true population frequency will typically be rarer).
The high baseline rate of rare, neutral mutations (e.g. Keinan & Clark, 2012) makes it
difficult to detect rare alleles that increase risk for common diseases. Although power can be
increased by jointly testing groups of variants in a gene (Wu et al., 2011), association testing
across all genes is likely to be under-powered at current sample sizes. Indeed, a recent
application of population-based exome sequencing in autism did not identify genes (Liu et
al., 2013), despite moderately large sample size and the success of the de novo paradigm.
Furthermore, many confirmed results from candidate gene sequencing studies of non-
psychiatric disease still fall short of exome-wide significance (Kiezun et al., 2012).
We therefore adopted a top-down strategy in which we studied a large set of genes with a
higher likelihood of playing a role in schizophrenia, based on existing genetic evidence (SI
section 7). We focused on ~2,500 genes implicated by unbiased, large-scale genome-wide
screens, including GWAS, CNV and de novo SNV studies, testing for enrichment of rare
case alleles. To prioritize individual genes, we characterized emerging signals with respect
to the genes and frequency and type of mutations. We coordinated analysis with an
independent trio exome sequencing study (Fromer et al., this issue) and note key points of
convergence below.
After alignment and variant calling of all samples jointly, we removed 11 subjects with low
quality data along with likely spurious sites and genotypes (SI sections 2 & 3). Per
individual, 93% (81%) of targeted bases were covered at ≥ 10-fold (30-fold). The final
dataset comprised 2,536 cases and 2,543 controls (ED Table 1a and ED Figure 2a). Cases
and controls had similar technical sequencing metrics, including total coverage, proportion
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of deeply covered targets, and overall proportion of non-reference alleles (ED Table 1b). We
observed 635,944 coding and splice-site passing variants of which 56% were singletons.
Using Sanger sequencing and ExomeChip data on these samples, we determined high
specificity and sensitivity for singletons (SI section 3).
We annotated variants with respect to RefSeq and combined five in silico algorithms to
predict missense deleteriousness (ED Table 1c and SI section 4). As expected, allelic types
more likely to impact protein function showed greater constraint: 69% of nonsense variants
were singletons, compared to 58% of missense and 51% of silent variants. Primary analyses
tested (1) disruptive variants (nonsense, essential splice site and frameshifts, N = 15,972
alleles with MAF < 0.1%), (2) disruptive plus missense variants predicted to be damaging
by all five algorithms (N = 50,369) and (3) disruptive plus missense variants predicted to be
damaging by at least one algorithm (N = 233,575). These groups are labeled (where NS
indicates nonsynonymous): disruptive, NSstrict and NSbroad. We also stratified most analyses
by allele frequency: (1) singletons; (2) up to 0.1% (10 or fewer minor alleles); (3) up to
0.5% (50 or fewer minor alleles). In the main geneset analyses, we empirically corrected for
multiple testing over the nine combinations of these factors (SI section 7).
The most significant SNV or indel association (P = 5×10-8) was for a common missense
allele in CCHCR1, in the MHC, a known risk locus; this top SNP was in LD with many
other schizophrenia-associated SNPs in the MHC. All P<10-5 variants were for either
common alleles or a few instances of likely aberrant variants that had escaped earlier
filtering (SI section 5). We performed two series of gene-based tests: a one-sided burden test
of an increased rare allele rate in cases, and the SKAT (Wu et al., 2011), which allows for
risk and protective effects. For both tests, the distribution of gene-based statistics broadly
followed a global null (ED Figure 2b).
Considering only disruptive variants, the genic test yielding the lowest nominal P-value was
for KYNU (kynureninase), showing 10 variants in cases and 0 in controls (ED Table 3 and
Supplementary Table 1); one novel nonsense mutation at chr2:143713804 (g.468T>A;
p.Y156*) was observed in 7 cases and not present in either the Exome Variant Server or
1000 Genomes Project. Although previous studies have suggested links between the
kynurenine pathway and schizophrenia (e.g. Linderholm et al., 2012), our P-value of
1.7×10-3 does not withstand correction for multiple testing, even if considering only the 246
genes with ≥ 10 rare disruptive mutations capable of achieving a nominally significant
result.
A polygenic burden of rare coding variants
We evaluated a polygenic burden of rare coding variants in cases, first selecting 2,546 genes
(~10% of the exome) based on prior genetic studies that we hypothesized to be enriched for
schizophrenia-associated mutations (SI section 6). Sources included genome-wide CNV
studies (Sullivan et al., 2012; Kirov et al., 2012), GWAS (Schizophrenia Psychiatric
Genome-Wide Association Study Consortium, 2011; Cross-Disorder Group of the
Psychiatric Genomics Consortium, 2013; Ripke et al., 2013) and exome sequencing of de
novo mutation (Girard et al., 2011; Xu et al., 2012; Fromer et al., current issue). In our
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sample, these genes had a significantly higher rate of rare (MAF < 0.1%) disruptive
mutations in cases compared to controls (P = 10-4 for 1,547 versus 1,383 mutations). The
enrichment was unlikely to represent technical or ancestry-related artifact because the P-
values controlled for potential differences in exome-wide burden in cases and controls, and
because we observed no differences exome-wide (P = 0.24). Furthermore, enrichment P-
values were empirically derived by permuting phenotypes within subgroups of m:n cases to
controls, matched on exome-wide identity-by-state, experimental batch and sex; the above
result withstood correction for multiple testing (Table 1). We observed similar results for
rarer (singletons P = 8×10-4) and more frequent alleles (MAF < 0.5%, P = 2×10-4). We also
observed case enrichment for the strictly defined set of damaging mutations (NSstrict P =
1.5×10-3) but not the broader set (NSbroad P = 0.13).
This enrichment suggests a polygenic burden of rare variants. Although not so marked as to
be detectable at the exome-wide level given the sample size, it is relatively concentrated in
genes that were found to be associated with schizophrenia by other methods. The mean
allelic effect was not large: in the primary comparison, the odds ratio was 1.12 (1.04 – 1.20
95% CI) for each MAF<0.1% disruptive mutation; 46% of cases carried one or more allele
in this primary set (0.62 per case) compared to 41% of controls (0.55 per control). At two
extremes, the modest mean effect could represent either that a subset of mutations are fully
penetrant or that every allele is associated but increases risk by only 12%, similar to
common alleles from GWAS. To extract subsets of potentially stronger-effect alleles, we
individually tested the constituent gene sources (Table 1, ED Figure 2c), focusing on
disruptive variants as they showed the strongest omnibus enrichment. For disruptive
mutations, 8 of 12 sets were nominally significant (P < 0.05), indicating that the initial
observation was not driven by a single category.
ARC, PSD-95 and calcium ion channel genes
Three of the smaller significantly enriched sets (the ARC and PSD-95 complexes and
calcium ion channel genes) had odds ratios > 5. We observed enrichment (P = 1.6×10-3) of
disruptive mutations among the 28 ARC complex genes: 9 mutations in 9 genes (all
singletons) in cases, 0 in controls yielding an odds ratio of 19.2 (2.4 – 2471 95% confidence
intervals, ED Table 3). Along with the NMDAR geneset (also significantly enriched), ARC
genes largely accounted for the overall PSD enrichment (P = 4×10-8) in Kirov et al. (2012),
in which four ARC genes had one or more de novo CNVs. Of note, in an independent
exome-sequencing study in trios, Fromer et al. (current issue) found that the ARC geneset
was enriched (P = 5×10-4) for nonsynonymous de novo SNVs and indels, with four genes
harboring six mutations (ED Table 8). The other PSD geneset with strong enrichment (P =
9×10-4, odds ratio = 5.1, 1.8 – 19.2 95% CI) was the PSD-95 complex, which contains 65
genes and overlaps with ARC. PSD genes are very highly conserved and play critical roles
in excitatory neural signaling components, as well as dendrite and spine plasticity. Further
categorization of neuronal genes based on subcellular localization (Kirov et al., 2012; ED
Table 4a) or associated mouse and human phenotypes (Bayés et al., 2011) did not yield
further enrichment.
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The other subset yielding a large odds ratio of 8.4 (2.03 – 77 95% CI) was the 26 voltage-
gated calcium ion channel genes (12 cases, 1 control disruptive singletons, P=2×10-3,
although the effect is attenuated when including recurrent alleles: 15/8, P = 0.021, see ED
Table 3). The singleton enrichment was predominantly driven by the pore-forming ř1 and
auxiliary ř2Ŝ subunits; of the ř1 subunits, the CaV1/L-type genes carried the most case
mutations, including two in CACNA1C, a gene implicated by GWAS of bipolar disorder and
schizophrenia (PGC Bipolar Disorder Group, 2012; Ripke et al., 2013). Calcium signaling is
involved in many cell functions including regulating gene expression (Dolmetsch et al.,
1998) and is critical for modulating synaptic plasticity (Yasuda et al., 2003). In a secondary
analysis of proteins found in the nano-environment of the calcium channel (Müller et al.,
2010), we observed independent enrichment for other ion channel transporters
(Supplementary Table S1), odds ratio 9.1 (2.2 – 83) for disruptive singletons (P = 1×10-3;
13/1 alleles).
Convergence with de novo studies
A line of convergence across studies was that genes carrying nonsynonymous de novo
mutations (Girard et al., 2011; Xu et al., 2012; Fromer et al., current issue) were enriched for
rare disruptive mutations (P = 1×10-3; Table 1 & ED Tables 7a, 7b). We observed a similar
result for the smaller class of genes carrying disruptive de novo mutations (P = 7×10-4, from
47 genes in our study); these genes included UFL1 (5/0 disruptive mutations, P = 0.03; 7/0
NSstrict, P = 0.008), SYNGAP1 (4/0 NSstrict, P = 0.04), and SZT2 (18/9 NSstrict, P = 0.049).
SYNGAP1 (Synaptic Ras GTPase Activating Protein 1) is a component of the NMDAR PSD
complex (Komiyama et al, 2002) and mutations in this gene are known to cause ID and
autism (Berryer et al, 2013).
Genes under previously associated CNV regions did not show significant enrichment of rare
disruptive mutations, although there was an enrichment of NSstrict mutations (P = 0.0044,
ED Table 5). Of the eleven CNV regions, only the 3q29 locus, that contains multiple genes
including DLG1 (Levinson et al., 2011), was significant (P = 0.0006) and withstood
correction for multiple testing.
Autism/ID genes including targets of FMRP
We next tested, as a single set, the 2,507 genes representing autism and ID candidates (SI
section 6), which yielded only nominal significance (P < 0.05) for disruptive and NSstrict
variants and no test survived correction for multiple testing (Table 2). Considering the
twelve constituent sets, genes from autism de novo studies showed no enrichment (ED
Figure 2c), despite greater sample size and number of disruptive de novo mutations. There
was no evidence for autism or ID genes curated from the literature (Betancur, 2011) or for
genes in the protein-protein interaction-derived subnetworks built around autism de novos
(O’ Roak et al., 2012).
The nominal omnibus signals arose largely from the Darnell et al. (2011) list of fragile X
mental retardation protein (FMRP) targets. FMRP is encoded by the gene FMR1 (the locus
of the Mendelian fragile X syndrome repeat mutation) and is an RNA-binding protein that
regulates translation and is needed at synapses for normal glutamate receptor signaling and
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neurogenesis (Callan & Zarnescu, 2011). Targets of FMRP are enriched for de novos in
autism (Darnell et al., 2011; Ascano et al., 2012; Iossifov et al., 2012); here we find
significant enrichment of disruptive singletons (P = 1.4×10-3, 289/223 case/control count,
OR = 1.3). These FMRP targets overlap with PSD genes (ED Table 4b), although were still
enriched independently (SI section 6). In addition, these genes were enriched in GWAS of
this sample (P < 10-3, SI section 9). Whereas the Darnell list is derived from mouse brain, a
second recently reported FMRP target list (Ascano et al., 2012) was generated from cultured
human embryonic kidney cells, using a different experimental approach (SI section 6). This
list has relatively little overlap with Darnell targets and, in contrast to the Darnell list, does
not show any enrichment for rare case mutations, for GWAS loci, or comparable overlap
with PSD genes (ED Table 4b).
Our results are perhaps surprising: unlike Fromer et al., we did not observe direct evidence
for overlap at the individual gene level with autism and ID, despite CNV studies showing
pleiotropic effects of individual loci. Nonetheless, at the broader level of genesets, all three
disorders showed enrichment for FMRP targets; autism and ID de novos also showed strong
enrichment in several PSD complexes enriched in our study, including NMDAR and
PSD-95, and (for ID) ARC (Fromer et al., current issue). At the least, our results suggest that
any overlap is far from complete, although more refined analyses in larger samples will be
needed before a clearer picture can emerge of which genes and pathways are shared and
which are specific to one disease.
Characterizing enrichment by variant type
To further characterize the observed enrichment with respect to mutational function and
frequency, we created a single “ composite”  set of 1,796 genes comprising all members of
the most prominently enriched sets (Supplementary Table S2). Rare disruptive mutations in
this set were present in 990 cases and 877 controls (for singletons, 645 to 530). Cases
carrying rare disruptive mutations did not appear to be phenotypically or clinically unusual
in terms of sex, ancestry, history of drug abuse, general medical conditions plausibly
etiologically related to psychosis, or epilepsy, although they did have a higher rate of
admissions noting co-morbid intellectual disability compared to other cases (P = 0.009, ED
Table 9b).
Figure 1 shows composite set enrichment across a range of conditions. As this set merges
other sets showing enrichment, it necessarily shows enrichment; it was not, however, due to
confounding effects of ancestry, sex or experimental wave (SI section 8). It was primarily
driven by singleton nonsense mutations across a large number of genes, as it was removed
or greatly attenuated when either singleton or nonsense mutations were excluded.
Considered alone, neither splice-site, frameshift, missense, silent nor noncoding mutations
showed enrichment at P<0.01. Different ways of defining damaging missense mutations did
not substantively impact results. Considering only nonsynonymous coding variants present
on ExomeChip, we did not observe enrichment. Rather, enrichment mainly reflected novel
variants (ED Table 6b), which is expected as most rare variants in our study are novel. We
also took an alternative approach, whereby instead of filtering variants on frequency, we
excluded genes with any control disruptive variants before calculating the burden of case
Purcell et al. Page 7
Nature. Author manuscript; available in PMC 2014 August 18.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
alleles; the composite set was still highly enriched (“ case-unique”  in Figure 1; see ED Table
6b & SI section 7). Finally, the enrichment could not be attributed to only a small number of
variants or genes (ED Figure 9a).
These findings do not preclude potentially important effects from other classes of rare
variation in specific genes or other genesets, although exploratory analyses of generic
genesets (e.g. based on Gene Ontology terms) did not unambiguously identify novel signals
after correction for multiple testing (SI section 7). We found preferential enrichment in
genes with high brain expression, but not for genes with a prenatally-biased developmental
trajectory (ED Figure 10). In fact, greater enrichment came from postnatally-biased genes.
Finally, while greatly attenuated compared to disruptive mutations, other categories
displayed nominal (0.01 < P < 0.05) enrichment in Figure 1 and strictly-defined damaging
missense mutations alone showed enrichment for ARC and NMDAR genesets (32/15 for
ARC, P = 0.007; ED Tables 6a & 8). Although rare coding alleles other than ultra-rare
nonsense mutations will undoubtedly contribute to risk, it will likely prove harder still to
elucidate such effects.
Rare variants, CNVs and common GWAS variants
We quantified the relative impact of common SNPs (indexed by a genome-wide polygene
score from independent GWAS samples from the Schizophrenia Psychiatric Genome-Wide
Association Study Consortium (2011)), rare CNVs (the burden of genic deletions) and
disruptive mutations in the composite set. Considering the same 5,079 individuals, all three
classes of variation were uncorrelated and significantly, independently and additively
enriched in cases compared to controls. From logistic regression, the relative effect sizes
(reduction in model R2) were 5.7%, 0.2% and 0.4% for GWAS, rare CNV and rare coding
variants (SI section 8). Although not a complete assessment, it indicates that for the current
sets of identifiably enriched alleles, common GWAS variants account for an order-of-
magnitude more heritability than this set of rare variants does. However, these estimates will
be diluted to varying degrees, due to unassociated variants being included. As a consequence
of this, and also the fact that true risk variants outside of composite set genes were not
considered here, this estimate represents a conservative lower bound on the contribution of
rare coding variation.
DISCUSSION
We have demonstrated a polygenic burden that increases risk for schizophrenia, primarily
comprised of many ultra-rare nonsense mutations distributed across many genes. Implicating
individual genes remains challenging, as genes that contributed to the highest-ranked sets
typically had unremarkable P-values, often around 0.5 with the gene containing only one or
two rare mutations. Nonetheless, we were able to detect several small and highly enriched
sets, notably of genes related to calcium channels and the postsynaptic ARC complex.
Across these ~50 genes, approximately 1% of cases carried a rare disruptive mutation likely
to have a considerable impact on risk. However, reported effect sizes will have a tendency to
over-estimate true population values (SI section 5).
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We add to previous work that has implicated disruption of synaptic processes in
schizophrenia (Kirov et al., 2012). The PSD is comprised of supramolecular multiprotein
complexes that detect and discriminate patterns of neuronal activity and regulate plasticity
processes responsible for learning (Migaud et al. 1998). Members of the membrane-
associated guanylate kinase (MAGUK) family of scaffold proteins, such as PSD-95, play a
key role in assembling ~2MDa complexes comprising calcium channels, including the
glutamate-gated NMDAR, voltage-gated calcium channels and ARC (Husi et al., 2000; Husi
& Grant, 2001; Fernandez et al., 2009; Müller et al., 2010). The genetic disruption of
MAGUKs and their associated components result in specific cognitive impairments in mice
and humans (Nithiantharajah et al., 2013). One possibility is that the genetic risk identified
here reflects altered tuning in calcium-dependent signaling cascades, triggered by NMDAR
(Steward & Worley, 2001) and L-type calcium channels (Waltereit et al., 2001), mediated
by postsynaptic MAGUK signaling complexes driving ARC synthesis.
Although we cannot yet use rare mutations to partition patients into more homogeneous
clinical subgroups, this will remain a central goal for future sequencing studies. The few
population-based common disease exome sequencing studies published to date, in
psychiatric (e.g. Liu et al., 2013) and non-psychiatric (e.g. Albrechtsen et al., 2012) diseases,
have not been successful in finding individual genes showing significant enrichment. Our
study yields similar findings for individual genes, but yields positive results when
considering gene sets. These current findings likely foreshadow the definitive identification
of individual genes in larger cohorts, following the trajectory of GWAS and other genetic
studies of complex disease.
METHODS SUMMARY
Sample ascertainment
Cases with schizophrenia were identified via the Swedish Hospital Discharge Register
(Ripke et al., 2013). Case inclusion criteria: ≥2 hospitalizations with a discharge diagnosis
of schizophrenia, both parents born in Scandinavia, age ≥18 years. Case exclusion criteria:
hospital register diagnosis of any disorder mitigating a confident diagnosis of schizophrenia.
Controls were randomly selected from Swedish population registers. Control inclusion
criteria: never hospitalized for schizophrenia or bipolar disorder, both parents born in
Scandinavia, age ≥18 years. All subjects provided informed consent; institutional human
subject committees approved the research.
Sequencing
The samples (2,536 cases, 2,543 controls) were sequenced using either the Agilent
SureSelect Human All Exon Kit (29Mb, n=132) or the Agilent SureSelect Human All Exon
v.2 Kit (33Mb). Sequencing was performed by IlluminaGAII or Illumina HiSeq2000.
Sequence data were aligned and variants called by the Picard (http://picard.sourceforge.net)
zBWA (Li & Durbin, 2009)/GATK (de Pristo et al., 2011) pipeline. Validation of selected
variants used Sanger sequencing. Based on validation and ExomeChip data, we estimated
high sensitivity and specificity of singleton calls. BAM and VCF files are available in the
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dbGaP study phs000473.v1 Sweden-Schizophrenia Population-Based Case-Control Exome
Sequencing.
Analysis
We used PLINK/Seq (http://atgu.mgh.harvard.edu/plinkseq/) to annotate variants according
to RefSeq gene transcripts (UCSC Genome Browser, http://genome.ucsc.edu). Single site
association used Fisher’ s exact test; primary gene-based association used a burden test and
the sequence kernel association test, SKAT (Wu et al., 2011). Analyses controlled for
ancestry and QC metrics. Genesets used were from recent literature. Genesets were
evaluated on the empirical distribution of the sum of individual gene burden statistics, and
incorporated an empirical correction for multiple testing. Odd ratios with 95% confidence
intervals used penalized maximum likelihood (Firth’ s method) for low cell counts. See the
SI for further details. Summary results are posted at http://research.mssm.edu/statgen/
sweden/
Extended Data
Extended Data Table 1
Sample and detected variant properties
a. Numbers of individuals in the final dataset, after individual-level QC. Finnish ancestry
was inferred by multidimensional scaling. P-values from Fisher’ s exact test. b. Technical
metrics for the cases and controls (after individual-level QC); P-values for two-sided test of
case/control differences (t-test). c. Properties of variants detected by exome sequencing.
Counts (N) and minor allele counts (MAC) for various classes of variant in the main exome
dataset, following all QC. Missense deleteriousness prediction algorithms and how they
were combined described in SI section 4.
a
Case/control status by sex (P = 5e-11) Status Male Female Female (%)
Control 1291 1252 49%
Case 1520 1016 40%
Case/control status by ancestry (P = 2e-12) Ancestry Control Case Case (%)
Swedish 2356 2197 48%
Finnish 139 274 66%
b
Sample and sequencing metrics Cases Controls
P (case vs.
control)
N 2536 2543 -
N (pre-QC) 2546 2545 -
Total number of reads 100,532,755 100,079,333 0.62
Filtered, unique reads aligned 68,940,753 68,339,964 0.26
Filtered, unique bases aligned 5,106,614,996 5,070,497,844 0.34
Mean target coverage 89.98 89.55 0.53
Percentage of target bases covered > 10x 92.83 92.85 0.55
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bSample and sequencing metrics Cases Controls
P (case vs.
control)
Percentage of target bases covered > 20x 87.30 87.30 0.93
Percentage of target bases covered > 30x 81.13 81.07 0.63
Percentage of targets w/out any bases covered at 2x 1.72 1.72 0.60
Mean number of non-reference genotypes per individual
(unfiltered)
18772.9 18786.6 0.13
Mean number of on-target singletons per individual
(unfiltered)
49.6 49.0 0.38
Mean dbSNP % per individual 98.3970% 98.3969% 1.00
c
Property Variant type N Mean MAC % singleton
All alternate alleles 635,944 103.37 56%
Functional class
 Noncoding 61,416 142.03 53%
 Silent 185,336 152.85 51%
 Missense 342,561 69.52 58%
 Non-essential splice site 25,450 127.04 54%
 Nonsense 9,022 20.68 69%
 Essential splice-site 4,394 16.18 70%
 Frameshifting indel 3,461 9.46 79%
In silico annotation of missenses
 LRT 168,437 34.55 62%
 Mutation Taster 167,316 19.90 63%
 PolyPhen2 (HumDiv) 130,719 28.84 62%
 PolyPhen2 (HumVar) 91,156 24.74 64%
 SIFT 140,345 43.85 61%
Primary variant groupings for analysis
 Singletons Gene disruptive 12,047 1.00 100%
Nonsyn (strict) 36,542 1.00 100%
Nonsyn (broad) 160,229 1.00 100%
 <0.1% MAF (1-10 alleles) Gene disruptive 15,972 1.56 75.4%
Nonsyn (strict) 50,369 1.65 72.5%
Nonsyn (broad) 233,575 1.78 68.6%
 <0.5% MAF (1-50 alleles) Gene disruptive 16,523 2.24 72.9%
Nonsyn (strict) 52,545 2.51 69.5%
Nonsyn (broad) 248,217 3.04 64.6%
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Extended Data Figure 10. Stratified enrichment analysis P-values by developmental trajectory of
expression in brain (BrainSpan & Human Brain Transcriptome (HBT) datasets)
a. Uncorrected P-values for a set of exploratory analyses in which we stratified genes in the
enrichment analyses by their developmental profile of brain expression. We used four
schemes to classify genes as “ brain expressed”  and/or “ biased”  with respect to prenatal or
postnatal expression (see SI section 6 and 10b below for details). We merged data on the
hippocampus and dorsolateral prefrontal cortex for the BrainSpan classifications; to mirror
the classification of Xu et al. (2012), we kept separate these two groupings for the HBT
dataset. Results presented for MAF<0.1% disruptive variants; similar results are obtained for
singletons with the exception that the “ K4”  prenatal enrichment signals are no longer
significant. In general, the most consistent enrichment across variant classes, classification
schemes and brain regions emerge for postnatally biased genes with high brain expression.
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b. Analysis of exome variants by developmental expression trajectory in human brain.
Genes are grouped by cluster analysis of human postmortem brain expression into eight
developmental trajectories, using RNA-sequencing data from the BrainSpan project. The top
row gives the number of genes per cluster and the cluster centers in log2-scaled RPKM
(reads per kilobase per million) values; solid and dotted solid lines indicate dorsolateral
prefrontal cortex (DLPFC) and hippocampus (HPC) respectively. The bottom two rows
show enrichment in the current study, relative to the exome-wide average, for singleton
disruptive mutations in cases compared to controls, either subsetting all genes by expression
profile (first row), or considering only genes in the composite set (second row). In both
cases, we only observed nominally (P < 0.01) significant enrichment for genes that are
postnatally biased. In contrast, a list of genes with loss-of-function (LoF) de novo mutations
(compiled and reported in Fromer et al.) shows strong enrichment for prenatal bias (see
Fromer et al. for details on how de novo enrichment was calculated). Alternative approaches
to classifying genes as prenatally or postnatally biased led to similar conclusions (SI section
6).
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Extended Data Figure 2. Ancestry and association summaries
a. Multidimensional scaling plot of ancestry in the Swedish sample, including HapMap CEU
and Finnish samples; showing sequenced individuals and the larger Swedish sample. b. Q-Q
plot for gene-based SKAT results (MAF < 5% coding variants). Similar, or more
conservative, profiles obtained for other subsets of variants. c Case enrichment of rare
(MAF<0.1%) and singleton disruptive mutations for the constituent sets of the primary/
schizophrenia gene set (top panel in green) and the secondary (autism/ID) geneset (bottom
panel in orange). The primary set is enriched in cases (MAF<0.1% disruptive mutations P =
10-4; singletons P = 8×10-4, significant after correction for multiple testing) whereas the
autism/ID shows only a modest trend (P = 0.04 and 0.03 for MAF<0.1% and singletons) and
is not significant after correction. X-axis represents −log10(P); OR is odds ratio. Number of
genes is for total in the set (whether or not they had a rare variant).
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Extended Data Table 3
Genes prioritized as more likely to harbor large-effect
alleles
Individual gene case/control counts, odds ratios and P-values for genes from primary
genesets with odds ratios > 5, and KYNU (top-ranked individual gene). Odds ratios are
calculated using Firth’ s method (penalized maximum likelihood logistic regression) and
shown with 95% confidence intervals. P-values are empirical, uncorrected one-sided burden
tests. FMRP target annotations are based on the Darnell et al. list only. Supplementary Table
S1 lists singleton variant and genotype information for the genes listed here.
Class Gene Singletons MAF < 0.1% Notes
ARC/PSD complex
CYFIP1 1/0 1/0 SCZ de novo (CNV)
BAIAP2 1/0 1/0 SCZ de novo (NS)
DLG1 1/0 1/0 SCZ de novo (NS), SCZ de novo
(CNV)
SLC25A3 1/0 1/0
GLUD1 1/0 1/0
CAMK2A 1/0 1/0 FMRP target
ATP1B1 1/0 1/0 AUT de novo (disruptive); FMRP
target
IQSEC2 1/0 1/0 ID de novo (disruptive); FMRP
target
MBP 1/0 1/0 FMRP target
Total 9/0 9/0
P = 0.0016 P = 0.0014
OR = 19.2 (2.4 - 2471) OR = 19.2 (2.4 - 2471)
PSD-95 genes
ABLIM1 1/0 1/0
ACO2 1/0 1/0 FMRP target
ANKS1B 3/1 3/1
ATP1B1 1/0 1/0 AUT de novo (disruptive); FMRP
target
ATP5A1 1/0 1/0 FMRP target
BAIAP2 1/0 1/0 SCZ de novo (NS)
CAMK2A 1/0 1/0 FMRP target
CAMK2B 2/0 2/0 FMRP target
DLG1 1/0 1/0 SCZ de novo (NS), SCZ de novo
(CNV)
GAPDH 1/0 1/0
IQSEC2 1/0 1/0 ID de novo (disruptive); FMRP
target
NRXN1 1/0 1/0 SCZ de novo (NS); AUT de novo
(disruptive); FMRP target
PRDX1 0/1 0/1
PRDX2 0/1 0/1
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Class Gene Singletons MAF < 0.1% Notes
SUCLA2 1/0 1/0 AUT de novo (disruptive)
SYNGAP1 1/0 1/0 SCZ de novo (disruptive); ID de
novo (disruptive); FMRP target
Total 17/3 17/3
P = 0.0017 P = 0.0009
OR = 5.1 (1.8 - 19.2) OR = 5.1 (1.8 - 19.2)
Voltage-gated calcium ion channel genes
CACNA1B 1/0 1/0 FMRP target
CACNA1C 2/0 2/0 SCZ & BP GWAS hit
CACNA1H 1/0 3/0
CACNA1S 2/0 2/3 SCZ & AUT de novos (NS)
CACNA2D1 1/0 1/0 PSD
CACNA2D2 3/0 3/0
CACNA2D3 0/0 3/0 AUT de novo (disruptive)
CACNA2D4 1/0 2/4
CACNB2 0/1 0/1
CACNB4 1/0 1/0 PSD
Total 12/1 15/8
P = 0.0021 P = 0.021
OR = 8.4 (2.03 - 77) OR = 2.1 (0.97 - 4.9)
Top disruptive gene-based
test
KYNU 3/0 10/0
P = 0.13 P = 0.0017
OR = 21.2 (2.7 - 2725)
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Extended Data Table 4
Extended results for all PSD genesets
a. Full PSD geneset association results. For all nine (3 annotation levels by 3 frequency
levels), P-values for enrichment of all genesets described and tested in Kirov et al. (2012).
In addition to the PSD genes (top five rows), enrichment statistics for presynaptic genes, and
neuronal genes clustered on the basis of subcellular location are given. Although the P-
values presented are uncorrected, we performed this analysis correcting for all 9×17=153
tests (by considering the distribution of the minimum empirical P-value across tests and sets,
as described in the SI). The values in bold are significant (Pcorrected < 0.05) after correction
for multiple testing. Both ARC and NMDAR network are significant after multiple test
correction, for the singleton NSstrict category. (Note: for ARC the disruptive singleton
category is, as reported in the primary test, highly significant and withstands correction for
multiple testing in that context; in this broader, less focused analysis it yields
Pcorrected=0.17; the majority of Pcorrected values (not shown in Table) are 1.00.) b. PSD and
FMRP-target genesets: descriptive statistics and overlap. Overlap between Darnell et al. &
Ascano et al. FMRP targets and PSD genes: for example, 57% (16/28) of ARC genes are in
the Darnell FMRP list. In contrast, only 7% (2/28) are in the Ascano list. There is a similar
trend across the three other major PSD subsets considered here: NMDAR network, PSD-95
and mGluR5 genes. Conversely, 22% of Darnell targets are in the PSD (human core)
compared to only 9% of Ascano targets.
a
Set N genes
Disruptive Nonsyn. (strict)
Singletons MAF< 0.1% MAF< 0.5% Singletons MAF< 0.1% MAF< 0.5%
PSD (human core) 685 0.0729 0.1019 0.1083 0.0058 0.1045 0.1285
 ARC 28 0.0016 0.0013 0.0014 0.0004 0.0018 0.0047
 NMDAR network 61 0.0154 0.0229 0.0225 0.0001 0.0007 0.0005
 mGluR5 39 0.1299 0.0861 0.0862 0.0628 0.0837 0.0900
 PSD-95 65 0.0015 0.0008 0.0008 0.0027 0.0204 0.0393
Pre-synapse 431 0.0187 0.0983 0.1458 0.2327 0.1811 0.3600
 Pre-synaptic active zone 173 0.0518 0.0487 0.0482 0.6162 0.6641 0.7082
 Synaptic vesicle 344 0.1030 0.3133 0.4151 0.1439 0.1093 0.2466
Cytoplasm 271 0.5851 0.1793 0.1034 0.8983 0.5351 0.6007
Early Endosomes 17 0.8917 0.7860 0.7826 0.2891 0.2420 0.2139
Endoplasmic Reticulum 97 0.3005 0.1882 0.2612 0.6615 0.2805 0.5036
ER/Golgi-derived vesicles 94 0.4258 0.2678 0.3644 0.3001 0.4977 0.6239
Golgi 31 0.5130 0.5493 0.5481 0.1998 0.0921 0.1338
Mitochondrion 197 0.0141 0.0259 0.0178 0.4351 0.0860 0.0671
Nucleus 167 0.1790 0.3029 0.2900 0.0626 0.1512 0.2728
Plasma membrane 50 0.7940 0.5659 0.5635 0.9416 0.8059 0.8091
Recycling Endosomes/trans-Golgi network 68 0.1502 0.0944 0.1556 0.5349 0.4514 0.5359
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bN
PSD (human core) FMRP target (Darnell) FMRP target (Ascano)
N % N % N %
PSD (human core) 685 - - 170 25% 80 12%
 ARC 28 - - 16 57% 2 7%
 NMDAR network 61 - - 32 52% 5 8%
 mGluR5 39 - - 25 64% 7 18%
 PSD-95 65 - - 30 46% 4 6%
Pre-synapse 431 213 49% 87 20% 31 7%
 Pre-synaptic active zone 173 121 70% 50 29% 10 6%
 Synaptic vesicle 344 162 47% 72 21% 27 8%
Cytoplasm 271 77 28% 16 6% 23 8%
Early Endosomes 17 6 35% 2 12% 1 6%
Endoplasmic Reticulum 97 13 13% 5 5% 4 4%
ER/Golgi-derived vesicles 94 24 26% 7 7% 4 4%
Golgi 31 2 6% 2 6% 4 13%
Mitochondrion 197 57 29% 6 3% 12 6%
Nucleus 167 19 11% 7 4% 19 11%
Plasma membrane 50 16 32% 6 12% 5 10%
Recycling Endosomes/trans-Golgi network 68 19 28% 3 4% 7 10%
Total 1509 685 45% 170 11% 80 5%
Extended Data Table 5
Association results for individual CNV regions
Focused enrichment analysis of genes under schizophrenia-associated CNV regions. The top
panel presents omnibus P-values testing all genes/regions (bold indicates significance after
correction for the four tests, Pcorrected = 0.016 for NSstrict MAF < 0.1% variants). This
enrichment arises solely from the 3q29 locus (middle panel; bold indicates significance after
correction of the 44 tests performed, Pcorrected = 0.024 for 3q29). Genes and NSstrict case/
control counts for the 3q29 region (lower panel).
Group Genes
Disruptive NSstrict
Singletons MAF < 0.1% Singletons MAF < 0.1%
CNV loci All 0.3279 0.4557 0.0843 0.0044
1q21.1 0.4533 0.6966 0.3205 0.1832
2p16.3 0.4775 0.3580 0.4703 0.2750
3q29 0.1054 0.0068 0.0123 0.0006
7q36.3 0.8642 0.5750 0.6411 0.2688
7q11.23 0.7199 0.6800 0.3329 0.2207
15q11.2 0.3208 0.1616 0.5138 0.1362
15q13.3 0.0883 0.3976 0.3672 0.2746
16p13.11 0.4194 0.3775 0.8346 0.4124
16p11.2 0.1613 0.1240 0.0655 0.0974
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Group Genes
Disruptive NSstrict
Singletons MAF < 0.1% Singletons MAF < 0.1%
17q12 0.7377 0.5205 0.4313 0.1385
22q11.21 0.9386 0.9977 0.5456 0.8754
Gene A/U Gene name
3q29 genes DLG1 5/0 discs, large homolog 1 (Drosophila)
RNF168 5/1 ring finger protein 168, E3 ubiquitin protein ligase
CEP19 2/0 centrosomal protein 19kDa
LRRC33 2/0 leucine rich repeat containing 33
PAK2 2/0 p21 protein (Cdc42/Rac)-activated kinase 2
PCYT1A 5/2 phosphate cytidylyltransferase 1, choline, alpha
PIGX 6/3 phosphatidylinositol glycan anchor biosynthesis, class X
FBXO45 1/0 F-box protein 45
NCBP2 1/0 nuclear cap binding protein subunit 2, 20kDa
PIGZ 1/0 phosphatidylinositol glycan anchor biosynthesis, class Z
TFRC 1/0 transferrin receptor (p90, CD71)
ZDHHC19 1/0 zinc finger, DHHC-type containing 19
C3orf43 4/2 chromosome 3 open reading frame 43
MFI2 15/12 antigen p97 (melanoma associated) identified by monoclonal antibodies 133.2
and 96.5
SLC51A 1/1 solute carrier family 51, alpha subunit
BDH1 0/1 3-hydroxybutyrate dehydrogenase, type 1
TCTEX1D2 0/1 Tctex1 domain containing 2
WDR53 0/1 WD repeat domain 53
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Extended Data Table 6
Further stratification of enrichment analyses by class of
variant
a. Geneset analyses for damaging missense mutations only. For the primary geneset and the
12 constituent subsets, a comparison of disruptive versus (strictlydefined) damaging
missenses, i.e. an independent set of variants. The omnibus result for the primary test is
modest (P=0.04) and did not withstand correction for multiple testing: as illustrated in
Figure 1 and the main text, the bulk of the enrichment signal we observe comes from
(singleton) disruptive mutations. Nonetheless, specific genesets such as ARC and the
NMDAR network are highly and independently enriched for missense variants. N represents
the number of genes with at least one mutation of this class observed in the sample. A/U
represent case/control counts of non-reference genotypes. OR represents the odds ratio (not
corrected for exome-wide rates) estimated by Firth’ s method for sets with small cell counts.
All tests are empirical and 1-sided (higher values expected in cases) as described in the main
text and methods. b. Enrichment analyses of novel and case-unique disruptive mutations.
For primary and secondary genesets (and constituent subsets) as well as the composite set:
results of three alternative burden analyses. First, focusing only on genes without any
control disruptive variants; no further frequency filter is imposed. Here “ N genes(A/U)”
indicates the number of genes with at least one disruptive variant, followed by the number of
genes with case-only disruptive mutations and (for comparison) the number with control-
only disruptive mutations. The “ A(U)”  column gives the number of case variants in the case-
only genes: the test statistic is based on the empirical distribution of this count. The U in this
field represents the similar quantity for controls (not explicitly used in the statistic). The
second set of analyses represent standard burden/enrichment tests (i.e. as Tables 2 and 4) but
stratified for novel versus known disruptive variants, according to dbSNP and the Exome
Sequencing Project/Exome Variant Server (ESP/EVS) database. Novel variants show
greater enrichment, although most rare variants observed in our study (both in cases and in
controls) are novel, so tests of novel variants will have greater power.
a
Primary geneset
Disruptive singletons Damaging missense (strict) singleton
P N A/U OR P N A/U OR
All primary genes 0.0008 905 852/716 1.20 0.0393 1357 2080/2001 1.04
SCZ de novo genes
 Exome sequencing (disruptive) 0.0349 40 56/38 1.48 0.5613 53 121/120 1.01
 Exome sequencing (nonsyn) 0.0059 332 384/309 1.25 0.2776 393 750/736 1.02
Copy number variants
 de novo CNV genes (Kirov et al,
2012)
0.0224 64 61/40 1.53 0.0593 90 125/112 1.12
 SCZ-associated CNV genes 0.3378 72 65/55 1.19 0.0310 111 148/119 1.25
GWAS
 Voltage-gated calcium channel genes 0.0021 9 12/1 8.40 0.4629 18 37/35 1.06
 Common SNPs (P < 1e-4 intervals) 0.1832 185 165/146 1.14 0.9246 268 359/395 0.91
 miRNA-137 targets 0.6643 140 98/100 0.99 0.1415 263 376/361 1.05
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aPrimary geneset
Disruptive singletons Damaging missense (strict) singleton
P N A/U OR P N A/U OR
Synaptic genes
 PSD (human core) 0.0824 219 172/145 1.19 0.0070 394 646/581 1.12
 ARC 0.0012 9 9/0 19.20 0.0069 19 32/15 2.14
 NMDAR network 0.0162 17 17/5 3.42 0.0003 34 76/45 1.70
 PSD-95 0.0018 16 17/3 5.10 0.0218 34 44/30 1.47
 mGluRS 0.1335 10 9/3 3.02 0.1715 22 52/36 1.45
b
Geneset
Case-unique burden analysis Known variants Novel variants
Singletons MAF < 0.1% Singletons MAF < 0.1%
P N genes(A/U) A(U) P N P N P N P N
Composite 0.0006 829(275/214) 378(297) 0.3733 145 0.2202 226 0.0002 683 0.0005 744
Primary 0.0022 1026(325/265) 440(367) 0.1003 191 0.0417 299 0.0074 831 0.0058 910
SCZ de novo genes
 Exome sequencing (disruptive) 0.0018 47(16/6) 29(12) 0.5514 13 0.2196 24 0.0362 35 0.0010 40
 Exome sequencing (nonsyn) 0.0037 371(108/80) 159(116) 0.3647 94 0.2064 144 0.0142 302 0.0071 326
Copy number variants
 de novo CNV genes 0.1267 79(25/17) 32(24) 0.0156 13 0.0116 24 0.0819 59 0.0679 67
 SCZ-associated CNV genes 0.7971 90(20/23) 24(32) 0.0355 23 0.0069 34 0.6081 63 0.9187 76
GWAS
 Voltage-gated calcium channel 0.0129 9(5/1) 10(1) 0.4922 2 0.7077 3 0.0006 7 0.0022 8
 P < 1e-4 intervals 0.1079 211(65/55) 91 (78) 0.0394 44 0.0409 69 0.4425 164 0.1882 180
 miRNA-137 targets 0.4498 156(52/50) 67(60) 0.9939 14 0.9972 22 0.3846 133 0.2757 147
Synaptic genes
 PSD (human core) 0.2234 244(92/79) 113(109) 0.5348 25 0.3072 40 0.1091 205 0.1629 226
 ARC 0.0008 9(9/0) 9(0) 0 0 0.0016 9 0.0013 9
 NMDAR network 0.0105 21(13/4) 18(4) 1.0000 1 0.6905 2 0.0075 16 0.0085 19
 PSD-95 0.0137 16(13/2) 14(2) 0.1218 1 0.1559 1 0.0034 15 0.0022 15
 mGluRS 0.1363 11(7/1) 8(1) 0 0.1458 1 0.1427 10 0.1826 11
Secondary (autism/ID) 0.0916 1249(348/314) 479(471) 0.1679 226 0.3543 352 0.1834 1041 0.0807 1143
De novo genes (exome
sequencing)
 Autism (disruptive) 0.662 65(17/17) 20(26) 0.4463 18 0.0781 23 0.6161 50 0.7009 56
 Autism (nonsyn) 0.220 407(101/96) 143(154) 0.3198 89 0.4487 133 0.6656 336 0.4960 369
 ID (disruptive) 0.262 8(4/1) 4(2) 1.0000 1 0.2747 3 0.3558 8 0.0578 8
 ID (nonsyn) 0.052 69(22/18) 35(28) 0.1303 14 0.0934 26 0.5331 62 0.3368 66
Neurodevelopmental candidates
 Betancur (2011), ASD
candidates
0.110 37(12/6) 16(7) 0.5824 9 0.7543 14 0.0484 24 0.0429 29
 Betancur (2011), ID
candidates
0.994 88(14/28) 16(38) 0.6553 16 0.7056 24 0.9488 74 0.9556 82
Autism PPI networks
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bGeneset
Case-unique burden analysis Known variants Novel variants
Singletons MAF < 0.1% Singletons MAF < 0.1%
P N genes(A/U) A(U) P N P N P N P N
 CHD8 network 1.000 1(0/1) 0(1) 0 0 1.0000 1 1.0000 1
 O’ Roak et al. 49-gene network 0.796 19(3/7) 4(16) 0.4755 5 0.7326 7 0.6081 30 0.7231 33
 O’ Roak et al. 74-gene network 0.654 33(6/13) 10(28) 0.6438 4 0.6667 4 0.7285 17 0.8411 19
Fragile × mental retardation
protein targets
 Darnell et al. targets 0.022 341(131/95) 169(133) 0.3048 39 0.3889 61 0.0007 288 0.0022 309
 Ascano et al. targets 0.449 517(134/131) 187(200) 0.5571 83 0.7281 128 0.5261 439 0.4089 482
 Ascano et al. FMRP/autism 0.423 33(10/6) 12(12) 0.0384 5 0.4624 11 0.6088 23 0.3954 28
Extended Data Table 7
Geneset analysis of de novo genes from schizophrenia
exome-sequencing studies
a. Test of case enrichment of rare variants in cases compared to controls, for genes with one
or more de novos in Fromer et al., Xu et al. and/or Girard et al. The P-values in bold are
significant at Pcorrected < 0.05, correcting for all 3×3×6 = 54 tests reported. b. Genes
nominally significant (no correction) that had an observed de novo in one of the
schizophrenia studies.
a
Set N genes
Disruptive Nonsyn. (strict)
Singletons MAF < 0.1% MAF < 0.5% Singletons MAF < 0.1% MAF < 0.5% Singletons
Fromer et al. (disruptive) 63 0.1484 0.0075 0.0034 0.7401 0.7324 0.6264 0.3347
Fromer et al. (nonsyn) 464 0.0004 0.0003 0.0016 0.0341 0.0057 0.0892 0.4688
Girard & Xu (disruptive) 24 0.0342 0.0082 0.0082 0.0423 0.0412 0.0602 0.0774
Girard & Xu (nonsyn) 151 0.6916 0.4124 0.4186 0.1510 0.1326 0.1285 0.2258
Combined SCZ (disruptive) 87 0.0319 0.0007 0.0003 0.3355 0.3162 0.2692 0.1325
Combined SCZ (nonsyn) 611 0.0053 0.0011 0.0055 0.0192 0.0024 0.0379 0.3408
b
Gene De novo study (type) Test N A/U P Gene name
ALDH1L2 Fromer et al.
(Nonsyn)
disruptive 6 10/3 0.028 aldehyde dehydrogenase 1 family, member
L2
CACNA1S Fromer et al.
(Nonsyn)
ns-strict 23 28/15 0.031 calcium channel, voltage-dependent, Ltype,
alpha 1S subunit
DLG1 Fromer et al.
(Nonsyn)
ns-strict 4 5/0 0.021 discs, large homolog 1 (Drosophila)
IGSF22 Fromer et al.
(Nonsyn)
disruptive 5 5/0 0.043 immunoglobulin superfamily, member 22
JARID2 Fromer et al.
(Nonsyn)
ns-strict 5 5/0 0.041 jumonji, AT rich interactive domain 2
LAMA4 Fromer et al.
(Nonsyn)
ns-strict 8 12/4 0.041 laminin, alpha 4
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bGene De novo study (type) Test N A/U P Gene name
NBEA Fromer et al.
(Nonsyn)
ns-strict 5 5/0 0.025 neurobeachin
POLL Fromer et al.
(Nonsyn)
disruptive 4 4/0 0.042 polymerase (DNA directed), lambda
PTK2B Fromer et al.
(Nonsyn)
ns-strict 4 4/0 0.044 PTK2B protein tyrosine kinase 2 beta
SHKBP1 Fromer et al.
(Nonsyn)
ns-strict 9 15/4 0.018 SH3KBP1 binding protein 1
SULF2 Fromer et al.
(Nonsyn)
ns-strict 5 7/0 0.007 sulfatase 2
SYNGAP1 Xu et al. (2012) (LoF) ns-strict 4 4/0 0.043 synaptic Ras GTPase activating protein 1
SZT2 Xu et al. (2012) (LoF) ns-strict 22 18/9 0.049 seizure threshold 2 homolog (mouse)
TANC1 Fromer et al.
(Nonsyn)
ns-strict 14 17/4 0.002 tetratricopeptide repeat, ankyrin repeat and
coiled-coil containing 1
TEP1 Xu et al. (2012)
(Nonsyn)
ns-strict 26 25/14 0.048 telomerase-associated protein 1
UFL1 Fromer et al. (LoF) ns-strict 4 7/0 0.008 UFM1-specific ligase 1
UFL1 Fromer et al. (LoF) disruptive 2 5/0 0.029 UFM1-specific ligase 1
Extended Data Table 8
Summary of observed likely-deleterious variants in
ARC genes across studies
For the 28 ARC genes, a summary of which genes had singleton disruptive, or damaging
missense, variants in the current study, compiled alongside the genes with de novo CNVs or
SNVs observed in Kirov et al. (2012) or Fromer et al. as well as the intellectual disability
(ID) de novo genes (compiled in Fromer et al.). The P-values at the bottom indicate that in
each comparison, the ARC geneset was significantly enriched.
ARC gene (N=28)
Current study de novo
CNV
(Kirov et
al.)
de novo SNV
(Fromer et
al.)
de novo SNV
in IDDisruptive Damaging missense (strict)
ACTN4 3/1
ARF5
ATP1A1 3/0
ATP1A3 2/1
ATP1B1 1/0 1/0
BAIAP2 1/0 NS(x2)
CAMK2A 1/0 1/0
CRMP1 1/3
CYFIP1 1/0 4/1 2 del; 2 dup
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ARC gene (N=28)
Current study de novo
CNV
(Kirov et
al.)
de novo SNV
(Fromer et
al.)
de novo SNV
in IDDisruptive Damaging missense (strict)
DLG1 1/0 2/0 1 del NS
DLG2 2/3 2 del LoF
DLG4 1/2 NS
DLGAP1 2/0 1 del
DLGAP2 1/0
DPYSL2 0/1
GLUD1 1/0 1/0
GLUL 2/0
GRIN1 2/0
HSPA8 LoF & NS
IQSEC1 4/1
IQSEC2 1/0 0/1 LoF
MBP 1/0 0/1
PKM2
PLP1
SLC25A3 1/0
SLC25A4
SLC25A5
STXBP1 LoF, NS(x2)
Counts: 9/0 32/15 8 SCNVs 6 SNVS 5 SNVS
P-value: 0.0016 0.0069 0.00025 0.0005 0.00002
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Extended Data Figure 9. Genic and phenotypic subset analyses for the composite set
a. Individual gene-ranking of composite set genes. Genes are ranked by their case burden of
rare disruptive mutations, from left to right, for the composite set. The squares along the
bottom indicate to which sets each gene belongs. The red and blue triangles represent case
and control counts for each gene. The lines above represent the statistical significance of the
best test for this set: that is, the significance of the top K genes, evaluated by permutation.
The black line represents results for the real data (disruptive MAF<0.1% composite set
analysis). The orange line represents the dummy condition, in which we artificially
constructed a set, where the number of genes, statistical enrichment, odds ratio and case/
control counts where similar to the real composite set. However, this set included the 25 top-
ranked genes from individual gene-based tests (disruptive MAF<0.1% variants), with the
remainder selected at random. The profile of the best test line is markedly different between
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the real and dummy gene sets (note: truncated at P=0.0001 reflecting the number of
permutations performed). Whereas the dummy P-value climbs quickly and then drops to the
final aggregate result, the true composite set line continues to climb after 200 genes,
indicating that many genes with a single disruptive mutation contribute to the observed set
enrichment (rather than a relatively small proportion of the 1,796 genes accounting for the
majority of the signal, as in the dummy set). b. Phenotypic characteristics of cases carrying
mutations. Relationship between clinical and demographic measures in schizophrenia cases
in relation to carrying one or more composite set disruptive risk alleles (MAF<0.1%).
Hospital Discharge Registry data (ICD9 codes) were available on 979 of the 990 case
carriers. All P-values (uncorrected) are two-sided from a case-only joint logistic regression
of carrier status (one or more risk alleles) on all admission and demographic variables
including year of first and last admissions. The four pairs of columns represent analyses in
which we varied the way in which the HDR admission data were represented (for drug
abuse, general medication condition, epilepsy and intellectual disability). “ # admissions”  =
independent variables are the untransformed number of admissions; “ >X admissions”  =
independent variable is binary 0/1 variable representing whether individuals had more than
X admissions. Of all clinical/demographic measures considered, we observed a nominally-
significant increased likelihood that cases carrying a disruptive allele in the composite set
have increased rates of secondary diagnoses of intellectual disability compared to other
cases (based on HDR ICD9 codes).
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Composite set geneset analysis, stratified by mutation type
Statistical significance (x-axis) for the composite gene set stratified by type and frequency of
mutation and other variables. Numbers to the right of each bar represent the number of
genes with at least one mutation in that category for the composite set. (S) represents
strictly-defined damaging missenses; (B) broadly-defined group. For the exome array
contrasts (in which ExomeChip sites were tested using the exome sequence calls), D
represents disruptive mutations, NS all nonsynonymous mutations.
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Table 1
Geneset analysis of primary schizophrenia candidate genesets
Enrichment test empirical P-values for rare (singleton; minor allele frequency (MAF) <0.1%; MAF < 0.5%)
variants from disruptive, NSstrict and NSbroad sets. P-values represent the relative case enrichment compared to
average exome-wide case/control difference. Bolded values are significant at Pcorrected<0.05. Initial
comparison corrects (based on the empirical distribution of minimum P-values) for the 9 correlated tests (top
panel). The lower panel focuses on the 12 subsets of the primary geneset, for disruptive variants only as they
showed the greatest enrichment for the entire primary set. Again, bold values are significant after correcting
for the 36 tests performed.
Variant type Geneset/subset N genes Singletons MAF < 0.1% MAF < 0.5%
Disruptive 0.0008 0.0001 0.0002
Nonsyn (strict) Primary 2,546 0.0059 0.0015 0.0110
Nonsyn (broad) 0.0986 0.1295 0.1126
Disruptive
SCZ de novo genes
 Exome sequencing (disruptive) 87 0.0319 0.0007 0.0003
 Exome sequencing (nonsyn) 611 0.0053 0.0011 0.0055
Copy number variants
 de novo CNV genes (Kirov et al, 2012) 234 0.0234 0.0039 0.0124
 SCZ-associated CNV genes 345 0.3308 0.4596 0.4376
GWAS
 Voltage-gated calcium channel genes 26 0.0019 0.0214 0.0212
 Common SNPs (P < 1e-4 intervals) 479 0.1794 0.0368 0.0037
 miRNA-137 targets 446 0.6573 0.5609 0.4747
Synaptic genes
 PSD (human core) 685 0.0808 0.1154 0.1256
 ARC 28 0.0016 0.0014 0.0014
 NMDAR network 61 0.0158 0.0251 0.0252
 PSD-95 65 0.0017 0.0009 0.0010
 mGluRS 39 0.1327 0.0900 0.0902
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Table 2
Geneset analysis of secondary autism/ID candidate genesets
Enrichment test empirical P-values for the secondary (autism/ID) geneset. As in Table 2, the top panel shows uncorrected P-values; tests significant after
multiple test correction are in bold (i.e. all Pcorrected >0.05). Because no class of variant is significant after multiple test correction for the omnibus test
(top panel), we applied and corrected for all 108 tests (9 conditions by 12 subsets) in the lower panel. The single category FMRP targets (Darnell et al.)
mainly reflects disruptive and NSstrict singleton enrichment.
Variant type Geneset/subset N genes Singletons MAF < 0.1% MAF < 0.5%
Disruptive 0.029 0.043 0.049
Nonsyn (strict) Autism/ID 2,507 0.052 0.008 0.013
Nonsyn (broad) 0.532 0.619 0.287
N genes Min. pcorrected (for 9×12=108 tests)
Disruptive, nonsyn(strict), & nonsyn(broad)
De novo genes (exome sequencing)
 Autism (disruptive) 128 1.000
 Autism (nonsyn) 743 1.000
 ID (disruptive) 30 0.070
 ID (nonsyn) 132 0.995
Neurodevelopmental candidates
 Betancur (2011), ASD candidates 112 1.000
 Betancur (2011), ID candidates 196 1.000
Autism PPI networks
 O’ Roak et al (2012), CHD8 network 6 1.000
 O’ Roak et al (2011), 49-gene network 49 1.000
 O’ Roak et al (2012), 74-gene network 74 1.000
Fragile × mental retardation protein targets
 Darnell et al. (2012) targets 788 0.010
 Ascano et al. (2012) targets 939 0.997
 Ascano et al. (2012) FMRP/autism overlap 93 0.993
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